Pfizer Commits $120M to Develop the COVID Drug Pax lovid.
The target for the company’s course output is 120 million. To the Editors, from NATHAN REIFF, Dated June 7th, 2022, and published at that time. The COVID Drug Pax lovid on June 6th, Pfizer Inc. (PFE) announced that it would be increasing its investment in U.S. manufacturing to meet the demand for Paxlovid, its oral treatment for COVID-19. The company will spend $120 million expanding capacity at its plant in